iShares 3 7 Year Treasury Bond ETF vs Relay Therapeutics Inc. Common Stock — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.48 (market cap $16.72B), while Relay Therapeutics Inc. Common Stock trades at $18.31 (market cap $3.82B). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 4.4× Relay Therapeutics Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| IEI | RLAY | |
|---|---|---|
Market Cap | $16.72B | $3.82B |
Volume | 3,963,319 | 4,332,079 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $20.75 |
52-Week Low | $113.17 | $6.03 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | — | $2.93B |
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.41, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though oscillators remain neutral. Recent dividend payments of $0.37-0.38 per share provide income stability. The stock faces headwinds from broader bond market volatility as Treasury yields reach multi-decade highs, impacting fixed-income related equities.
The outlook remains cautious amid persistent bond market pressures. While dividend payments offer some support, the bearish technical setup and elevated Treasury yields create near-term challenges. Investment opportunity exists for income-focused investors, but requires careful monitoring of interest rate developments and bond market stability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →